AVADEL PHARMACEUTICALS PLC

Delisted

CIK 1012477fmd_1WWQS20DD526QC4Q7EC7YX14QYManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Sep 30, 2025, 60 periods

Income Statement · Annual · Millions · USD
Line item	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Total revenues	173	150	173	103	59	22	0	0	28	169
Cost of revenue	11	13	16	18	12	6	0	0	1	15
Gross profit	162	137	157	86	47	17	0	0	27	154
Research and development	26	35	33	39	33	20	17	21	13	15
Selling, general and administrative	22	44	59	100	30	32	68	75	152	181
Total operating expenses	–	–	–	–	–	–	86	99	165	196
Operating income	71	(5)	90	(105)	(24)	6	(86)	(99)	(138)	(42)
Interest expense	0	1	1	11	12	13	10	12	10	11
Interest and investment income	–	–	–	–	–	–	–	–	–	–
Other non-operating income (expense)	(5)	(7)	2	2	(0)	(0)	0	–	–	–
Income before taxes	78	(10)	93	(113)	(39)	(5)	(93)	(111)	(161)	(49)
Income tax expense	36	32	24	(18)	(5)	(12)	(16)	26	(1)	(0)
Net income from continuing operations	42	(41)	68	(95)	(33)	7	(77)	(137)	(160)	(49)
Net income	42	(41)	68	(95)	(33)	7	(77)	(137)	(160)	(49)